These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 16299255

  • 1. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
    Cui W, Yu CH, Hu KQ.
    Clin Cancer Res; 2005 Nov 15; 11(22):8213-21. PubMed ID: 16299255
    [Abstract] [Full Text] [Related]

  • 2. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
    Cui W, Hu SX, Tang ZY, Hu KQ.
    Anticancer Drugs; 2008 Oct 15; 19(9):891-7. PubMed ID: 18766003
    [Abstract] [Full Text] [Related]

  • 3. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G.
    FASEB J; 2001 Dec 15; 15(14):2742-4. PubMed ID: 11606477
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 15; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 5. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S, Wu K, Feitelson MA, Liu J, Fan D.
    Mol Carcinog; 2009 Jan 15; 48(1):56-65. PubMed ID: 18506760
    [Abstract] [Full Text] [Related]

  • 6. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST.
    Cancer Res; 2005 May 01; 65(9):3691-9. PubMed ID: 15867364
    [Abstract] [Full Text] [Related]

  • 7. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ.
    Clin Cancer Res; 2005 Mar 01; 11(5):1999-2007. PubMed ID: 15756026
    [Abstract] [Full Text] [Related]

  • 8. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
    Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grösch S.
    Biochem Pharmacol; 2004 Apr 15; 67(8):1469-78. PubMed ID: 15041464
    [Abstract] [Full Text] [Related]

  • 9. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N.
    Clin Cancer Res; 2005 Sep 15; 11(18):6738-44. PubMed ID: 16166455
    [Abstract] [Full Text] [Related]

  • 10. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
    Hu KQ, Yu CH, Mineyama Y, McCracken JD, Hillebrand DJ, Hasan M.
    Int J Oncol; 2003 Apr 15; 22(4):757-63. PubMed ID: 12632065
    [Abstract] [Full Text] [Related]

  • 11. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment.
    Janssen A, Maier TJ, Schiffmann S, Coste O, Seegel M, Geisslinger G, Grösch S.
    Eur J Pharmacol; 2006 Jul 01; 540(1-3):24-33. PubMed ID: 16730702
    [Abstract] [Full Text] [Related]

  • 12. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
    Wang L, Chen W, Xie X, He Y, Bai X.
    Exp Oncol; 2008 Mar 01; 30(1):42-51. PubMed ID: 18438340
    [Abstract] [Full Text] [Related]

  • 13. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, Liang L, Guo M, Fenton B, Okunieff P, Ding I.
    Am J Clin Oncol; 2003 Aug 01; 26(4):S103-9. PubMed ID: 12902866
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
    Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G, Grösch S.
    Biochem Pharmacol; 2008 Jul 15; 76(2):179-87. PubMed ID: 18547544
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
    Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL.
    Cancer Res; 2002 Feb 01; 62(3):625-31. PubMed ID: 11830509
    [Abstract] [Full Text] [Related]

  • 19. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models.
    Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN.
    Cancer Res; 2000 Nov 01; 60(21):6045-51. PubMed ID: 11085526
    [Abstract] [Full Text] [Related]

  • 20. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.
    Cancer Res; 2002 Nov 15; 62(22):6706-11. PubMed ID: 12438270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.